This systematic review consolidates 170 published cases of sternoclavicular septic arthritis plus 10 new cases to define its epidemiology, microbiology, and management. It addresses a condition that is rare overall but disproportionately common in IV drug users, with a microbiology that shifted substantially after the 1980s.
Sternoclavicular septic arthritis is a diagnosis that is easy to miss and dangerous to undertreat. The joint is tender in 90% of patients, but fever is absent in 35% and leukocytosis in 44% — so a patient with anterior chest pain, normal vitals, and a normal CBC still needs this on the differential.
The imaging algorithm is clear: get CT or MRI on every patient. Plain films are normal at presentation in 85% of cases, while CT shows at least one abnormality in 100%. The scan dictates surgical planning: limited disease can be managed medically, but osteomyelitis, chest wall phlegmon, retrosternal abscess, or mediastinitis mandates en-bloc resection of the joint.
For empiric antibiotics, cover Staphylococcus aureus as the primary target. The old teaching that Pseudomonas is the organism in IV drug users is no longer accurate. Since 1981, S. Aureus has caused 77% of IDU cases. Add MRSA coverage (vancomycin) when the patient has IV drug use, hemodialysis, central line access, or recent hospitalization.
Duration matters: 4 weeks of antibiotics for uncomplicated cases, 6 weeks when osteomyelitis or mediastinitis is present. Functional outcomes after resection are generally good because the sternoclavicular joint contributes modestly to upper extremity motion.
This systematic review consolidates 170 published cases of sternoclavicular septic arthritis plus 10 new cases to define its epidemiology, microbiology, and management. It addresses a condition that is rare overall but disproportionately common in IV drug users, with a microbiology that shifted substantially after the 1980s.
Sternoclavicular septic arthritis is a diagnosis that is easy to miss and dangerous to undertreat. The joint is tender in 90% of patients, but fever is absent in 35% and leukocytosis in 44% — so a patient with anterior chest pain, normal vitals, and a normal CBC still needs this on the differential.
The imaging algorithm is clear: get CT or MRI on every patient. Plain films are normal at presentation in 85% of cases, while CT shows at least one abnormality in 100%. The scan dictates surgical planning: limited disease can be managed medically, but osteomyelitis, chest wall phlegmon, retrosternal abscess, or mediastinitis mandates en-bloc resection of the joint.
For empiric antibiotics, cover Staphylococcus aureus as the primary target. The old teaching that Pseudomonas is the organism in IV drug users is no longer accurate. Since 1981, S. Aureus has caused 77% of IDU cases. Add MRSA coverage (vancomycin) when the patient has IV drug use, hemodialysis, central line access, or recent hospitalization.
Duration matters: 4 weeks of antibiotics for uncomplicated cases, 6 weeks when osteomyelitis or mediastinitis is present. Functional outcomes after resection are generally good because the sternoclavicular joint contributes modestly to upper extremity motion.